The confirmation came from two separate sets of in vitro studies conducted at leading institutions. Research led by Professor Tim Bull at City St George's University of London demonstrated that RHB-204 could kill Mycobacterium avium subspecies paratuberculosis, commonly called MAP, in long-term intracellular culture …
PRKAG2 syndrome is a rare, hereditary condition caused by mutations in the PRKAG2 gene, which produces a regulatory subunit of an enzyme called AMPK. Mutations in this gene cause AMPK to remain abnormally active, leading to the accumulation of glycogen within heart muscle cells. …
WISeQey's preliminary unaudited results for the nine months ended September 30, 2026, show revenue of $17 million compared to $11 million in the equivalent period a year earlier — a 55% year-over-year increase. The group held approximately $471 million in consolidated cash, cash equivalents, …
The acquisition was announced by The Office Gurus (TOG), which functions as the Contact Centers segment within Superior Group of Companies. Select VoiceCom operates delivery centers in Cebu City and Davao — two of the Philippines' largest metropolitan areas outside Manila — and has …
One of the more consequential milestones reported for the quarter was the outcome of a Phase 1 driving simulation trial of GlyphAllo, Seaport's allopregnanolone-based drug candidate. Sleep-disrupting side effects, particularly residual sedation that affects next-day functioning, have been a limitingFactorfor neuroactive steroid therapies in …
The company generated revenues of $55.6 million in the third quarter, up 20.2% from the $46.2 million recorded in the same period of 2025. For the nine-month period ending September 30, 2026, the growth trajectory was similarly upward, with management noting record figures across …
Oncology testing volumes accelerated to 32% growth in the quarter, underpinned by expanding adoption of the company's diagnostic platform. The Minimal Residual Disease segment — which involves detecting traces of cancer remaining after treatment — saw particularly rapid expansion, with approximately 12,000 tests performed …
The company plans to hold a conference call at 9:00 a.m. Eastern Time — 8:00 a.m. Central Time — on the same day results are published. Investors and analysts who want to participate can access the call through a direct phone dial link at …
The INFORM-MS trial evaluated intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in patients with non-active secondary progressive MS (na-SPMS) — a disease state characterized by the gradual accumulation of neurological disability independent of acute relapses. The dual primary endpoints required the trial to …
The document outlines how T-Mobile restructured its security operations across employee access controls, customer-facing authentication, and network defense layers. Rather than providing aMarketingsummary, the company has presented measurable outcomes alongside the methodology used to achieve them. Among the metrics cited, the carrier recorded a …